

**TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS**

**Name of the Issue:**

**Vijaya Diagnostic Centre Limited**

**1. Type of Issue (IPO/FPO)**

IPO

**2. Issue Size (Rs. Cr)**

INR 1894.256 Cr

**3. Grade of issue along with name of the rating agency**

**Name**

NA

**Grade**

NA

**4. Subscription Level (Number of times)**

**4.24861** (excluding Anchor Investor Portion and after removing multiple and duplicate bids and technical rejections cases)

Source – Minutes of Basis of Allotment dated September 08, 2021

**5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges**

<b>Particulars</b>	<b>Percentage</b>
(i) allotment in the issue	21.78%*
(ii) at the end of the 1st Quarter immediately after the listing of the issue <sup>^</sup>	NA
(iii) at the end of 1st FY (March 31, 2022) <sup>^</sup>	NA
(iv) at the end of 2nd FY (March 31, 2023) <sup>^</sup>	NA
(v) at the end of 3rd FY (March 31, 2024) <sup>^</sup>	NA

<sup>(^)</sup> QIB Holding not disclosed as reporting for relevant period / fiscal years has not been completed

**(\*) As a % of total paid up capital as per prospectus dated September 06, 2021**

## 6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated

(Rs in Crores)

Parameters	1st FY (March 31, 2022)*	2nd FY (March 31, 2023)*	3rd FY (March 31, 2024)*
Income from operations	N.A.	N.A.	N.A.
Net Profit for the period	N.A.	N.A.	N.A.
Paid-up equity share capital	N.A.	N.A.	N.A.
Reserves excluding revaluation reserves	N.A.	N.A.	N.A.

\* Financials not disclosed as reporting for the relevant fiscal years has not been completed.

## 7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited and the National Stock Exchange of India Limited.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)*	N.A.
(ii) at the end of 2nd FY (March 31, 2023)*	N.A.
(iii) at the end of 3rd FY (March 31, 2024)*	N.A.

\* Trading status not disclosed as reporting for the relevant fiscal years has not been completed

## 8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)*	N.A.	N.A.
(ii) at the end of 2nd FY (March 31, 2023)*	N.A.	N.A.
(iii) at the end of 3rd FY (March 31, 2024)*	N.A.	N.A.

\*Changes in directors not disclosed as reporting for relevant fiscal years has not been completed

## 9. Status of implementation of project/ commencement of commercial production

- (i) **As disclosed in the offer document: NA**
- (ii) **Actual implementation: NA**
- (iii) **Reasons for delay in implementation, if any: NA**

**10. Status of utilization of issue proceeds**

(i) As disclosed in the offer document: NA

(ii) Actual utilization: NA

(iii) Reasons for deviation, if any: NA

**11. Comments of monitoring agency, if applicable**

(a) Comments on use of funds	<b>NA</b>
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

**12. Pricing Data**

**Issue Price (Rs.):** 531  
**Designated Stock Exchange:** NSE  
**Listing Date:** September 14, 2021

Price parameters	At close of listing day (i.e. September 14, 2021)	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of 1st FY after the listing of the issue (March 31, 2022)*		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	620.10	NA	NA	NA	NA	NA
NIFTY50	17,380.00	NA	NA	NA	NA	NA
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2023)*			As at the end of 3rd FY after the listing of the issue (March 31, 2024)*		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
	NA	NA	NA	NA	NA	NA

Market Designated Exchange (NSE)	Price on Stock					
NIFTY50		NA	NA	NA	NA	NA
Sectoral Index		NA	NA	NA	NA	NA

Source: NSE website

\* Pricing Data not disclosed as reporting for the relevant fiscal years has not been completed

**13. Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)**

Accounting ratio		As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2022) <sup>(2)</sup>	At the end of 2nd FY (March 31, 2023) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2024) <sup>(2)</sup>
EPS	Issuer:	--	--	--	--
	Consolidated (Basic)	8.26	N.A	N.A	N.A
	Consolidated (Diluted)	8.26	N.A	N.A	N.A
	Peer Group:	--	--	--	--
	Dr. Lal Path Labs Limited	Basic: 35.33 Diluted: 35.25	N.A	N.A	N.A
	Metropolis Healthcare Limited	Basic: 35.97 Diluted: 35.79	N.A	N.A	N.A
	Industry Avg:	N.A	N.A	N.A	N.A
P/E	Issuer:	--	--	--	--
	Consolidated (Basic)	64.29	N.A	N.A	N.A
	Consolidated (Diluted)	64.29	N.A	N.A	N.A
	Peer Group:	--	--	--	--
	Dr. Lal Path Labs Limited	107.3	N.A	N.A	N.A

	Metropolis Healthcare Limited	74.4	N.A	N.A	N.A
	Industry Composite:	90.8	N.A	N.A	N.A
RoNW (%)	<b>Issuer:</b>	--	--	--	--
	Consolidated	23.64%	N.A	N.A	N.A
	Peer Group:	--	--	--	--
	Dr. Lal Path Labs Limited	23.42%	N.A	N.A	N.A
	Metropolis Healthcare Limited	25.91%	N.A	N.A	N.A
	Industry Composite:	N.A	N.A	N.A	N.A
NAV	<b>Issuer:</b>	--	--	--	--
	Consolidated	35.23	N.A	N.A	N.A
	Peer Group:	--	--	--	--
	Dr. Lal Path Labs Limited	149.38	N.A	N.A	N.A
	Metropolis Healthcare Limited	138.23	N.A	N.A	N.A
	Industry Avg:	N.A	N.A	N.A	N.A

**Notes:**

(1) Prospectus dated September 06, 2021

(2) Not disclosed as the reporting for the relevant fiscal years has not been completed.

**Other Notes:**

- All the financial information for listed industry peer mentioned above is on a consolidated basis and is sourced from the annual audited financial results of the company for the year ended March 31, 2021
- Vijaya Diagnostic Centre Limited has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity shares of face value of ₹10 each to Equity Shares of face value of ₹1 each. Further subsequent to March 31, 2021, pursuant to a Board resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, our Company has capitalised the securities premium account to issue bonus Equity Shares in the ratio of 5 Equity Shares for every 4 Equity Shares held. Basic and diluted EPS are considered post sub-division and bonus issue.
- P/E Ratio for listed peers has been computed based on the closing market price of equity shares on BSE on August 11, 2021, divided by the Basic EPS.
- Net Profit is the Profit for the year attributable to equity shareholders of the Company
- Return on net worth %: Profit for the year attributable to equity shareholders of the Company divided by net worth as attributable to equity shareholders of the Company at the end of the year
- Net worth has been computed as sum of paid-up share capital and other equity.

- NAV is computed as the closing net worth divided by the closing outstanding number of equity shares. Vijaya Diagnostic Centre Limited has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity shares of face value of ₹10 each to Equity Shares of face value of ₹1 each. Further subsequent to March 31, 2021, pursuant to a Board resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, bonus share has been issued in the ratio of 5 equity shares for every 4 equity shares. Net asset value per share is considered post sub-division and bonus issue

**14. Any other material information**

Particulars	Date
NIL	

Source- Stock Exchange Filings

All the above information has been updated till September 14, 2021 unless indicated otherwise